SANA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SA

Mkt Cap

$681.0M

Volume

2.02M

Next Earnings

November 5th

Loading chart

SA

SANASana Biotechnology, Inc. Common Stock

SANA

Pay with—

Available Balance0.00

SA

Mkt Cap

$679.5M

Volume

2.02M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss RaceKailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showing up to 12.1% weight loss in oral formulation trials.Benzinga · Apr 17, 2026

Stock Market Today: Dow Jones, S&P 500 Futures Rise As JD Vance Touts 'Good Deal' If Iran Meets US 'Red Lines'—Sana, Chevron In FocusU.S. stock futures rose on Tuesday following Monday's rally, with major indices trading higher. Vice President JD Vance signaled potential progress in Iran nuclear talks if Tehran meets U.S. demands. Investors await March producer price index data. Key movers include Sana Biotechnology surging 20% on Mayo Clinic collaboration, ChargePoint jumping 6.63% on insider buying, and Chevron declining despite a Venezuela oil production agreement. Professor Jeremy Siegel warns of near-term market caution due to rising oil prices and money growth concerns.Benzinga · Apr 14, 2026

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen PlatformSana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.GlobeNewswire Inc. · Dec 8, 2025

Sana Biotech Stock — The Next '100-Bagger'?Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.Benzinga · Oct 15, 2025

Quell Therapeutics Establishes World-Class Scientific Advisory BoardQuell Therapeutics has formed a Scientific Advisory Board comprising leading experts in immunology, T-regulatory cell biology, and autoimmune diseases to guide its innovative CAR-Treg cell therapy development.GlobeNewswire Inc. · Aug 27, 2025

Sana Biotechnology Announces Pricing of Public OfferingSana Biotechnology has priced a public offering of 20,895,522 shares at $3.35 per share and pre-funded warrants, expecting to raise approximately $75 million. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are joint book-running managers for the offering.Benzinga · Aug 7, 2025

Sana Biotechnology Announces Pricing of Public OfferingSana Biotechnology plans to raise approximately $75 million through a public offering of 20,895,522 common shares and pre-funded warrants at $3.35 per share, with Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen as joint book-running managers.GlobeNewswire Inc. · Aug 7, 2025

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of DirectorsDraig Therapeutics, a clinical-stage neuropsychiatric drug development company, appointed Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. Dr. Williams brings over 30 years of biotech leadership experience from companies like Biogen and Amgen.GlobeNewswire Inc. · Jul 15, 2025

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law FirmSana Biotechnology, Inc. (SANA) is facing a securities fraud lawsuit alleging the company made false and misleading statements about its financial position and product pipeline, leading to investor losses.Benzinga · May 19, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana BiotechnologySana Biotechnology is facing a securities class action lawsuit alleging the company made false and misleading statements about its financial capacity and the prospects of its product candidates. The lawsuit claims Sana overstated its financial position and was likely to decrease funding or discontinue certain programs.GlobeNewswire Inc. · May 14, 2025

to start trading

SA

SANASana Biotechnology, Inc. Common Stock

SANA

Pay with—

Available Balance0.00

Your PositionYou don't own any SANA yet.

Related Tickers

Earnings